HUP0402324A3 - [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them - Google Patents

[1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them

Info

Publication number
HUP0402324A3
HUP0402324A3 HU0402324A HUP0402324A HUP0402324A3 HU P0402324 A3 HUP0402324 A3 HU P0402324A3 HU 0402324 A HU0402324 A HU 0402324A HU P0402324 A HUP0402324 A HU P0402324A HU P0402324 A3 HUP0402324 A3 HU P0402324A3
Authority
HU
Hungary
Prior art keywords
triazolo
adenosine
pyridine
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0402324A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HUP0402324A2 publication Critical patent/HUP0402324A2/hu
Publication of HUP0402324A3 publication Critical patent/HUP0402324A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0402324A 2001-11-30 2002-11-26 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them HUP0402324A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
PCT/US2002/037915 WO2003048163A1 (en) 2001-11-30 2002-11-26 [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (2)

Publication Number Publication Date
HUP0402324A2 HUP0402324A2 (hu) 2005-02-28
HUP0402324A3 true HUP0402324A3 (en) 2008-09-29

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402324A HUP0402324A3 (en) 2001-11-30 2002-11-26 [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them

Country Status (18)

Country Link
US (2) US6875772B2 (enExample)
EP (1) EP1453836B1 (enExample)
JP (2) JP4429724B2 (enExample)
KR (1) KR20050044600A (enExample)
CN (1) CN1688581A (enExample)
AR (1) AR037681A1 (enExample)
AT (1) ATE358130T1 (enExample)
AU (1) AU2002352933A1 (enExample)
CA (1) CA2468658C (enExample)
DE (1) DE60219196T2 (enExample)
ES (1) ES2283625T3 (enExample)
HU (1) HUP0402324A3 (enExample)
IL (1) IL161573A0 (enExample)
MX (1) MXPA04005158A (enExample)
PE (1) PE20030653A1 (enExample)
TW (1) TW200300689A (enExample)
WO (1) WO2003048163A1 (enExample)
ZA (1) ZA200404168B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005158A (es) * 2001-11-30 2004-08-11 Schering Corp Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
TW200304825A (en) * 2002-03-12 2003-10-16 Wyeth Corp Process for making chiral 1,4-disubstituted piperazines
WO2004029056A1 (ja) * 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
WO2005044245A1 (en) * 2002-12-19 2005-05-19 Schering Corporation USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
WO2006131524A1 (en) * 2005-06-08 2006-12-14 Neurosearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2007027987A2 (en) * 2005-09-02 2007-03-08 Mount Cook Biosciences, Inc. Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
EP3814355A4 (en) 2018-06-26 2022-06-08 Zhejiang Vimgreen Pharmaceuticals, Ltd PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
US20230048888A1 (en) * 2019-12-26 2023-02-16 Zhejiang Vimgreen Pharmaceuticals, Ltd. Use of triazolotriazine derivative in treatment of diseases
MX2023012338A (es) * 2021-04-23 2023-10-30 Chong Kun Dang Pharmaceutical Corp Compuesto como antagonista del receptor de adenosina a2a y composicion farmaceutica que comprende al mismo.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
JP4195729B2 (ja) * 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
WO1999043678A1 (en) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for parkinson's disease
BR9914040A (pt) * 1998-09-22 2002-01-15 Kyowa Hakko Kogyo Kk Derivados de [1,2,4]triazolo[1,5-c]pirimidina e seu uso, medicamento, antagonista, agente para prevenir ou tratar doenças, bem como processo para prevenção ou tratamento de distúrbios
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法
JP4574112B2 (ja) 2000-05-26 2010-11-04 シェーリング コーポレイション アデノシンａ２ａレセプターアンタゴニスト
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
MXPA04005158A (es) * 2001-11-30 2004-08-11 Schering Corp Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol.

Also Published As

Publication number Publication date
KR20050044600A (ko) 2005-05-12
US6875772B2 (en) 2005-04-05
JP4429724B2 (ja) 2010-03-10
HUP0402324A2 (hu) 2005-02-28
HK1064097A1 (en) 2005-01-21
US20030191130A1 (en) 2003-10-09
DE60219196D1 (de) 2007-05-10
TW200300689A (en) 2003-06-16
JP2005511697A (ja) 2005-04-28
ES2283625T3 (es) 2007-11-01
AR037681A1 (es) 2004-12-01
WO2003048163A1 (en) 2003-06-12
EP1453836B1 (en) 2007-03-28
CA2468658A1 (en) 2003-06-12
ATE358130T1 (de) 2007-04-15
ZA200404168B (en) 2005-09-02
DE60219196T2 (de) 2008-01-03
JP2010018634A (ja) 2010-01-28
PE20030653A1 (es) 2003-08-04
IL161573A0 (en) 2004-09-27
MXPA04005158A (es) 2004-08-11
CA2468658C (en) 2009-04-14
US7078408B2 (en) 2006-07-18
AU2002352933A1 (en) 2003-06-17
EP1453836A1 (en) 2004-09-08
CN1688581A (zh) 2005-10-26
US20050113380A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
HUP0402324A3 (en) [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
HUP0600239A2 (en) 5-amino-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, process for their preparation, their use as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
HUP0402270A3 (en) [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
HUP0401047A3 (en) Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same
IL160878A0 (en) Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
IL151849A0 (en) Pyrido [2,3-d] pyrimidine and pyrimido [4,5-d] pyrimidine nucleosides
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
IL128869A (en) ARYSULFONYL-SUBSTITUTED-PYRAZOLO [1,5-a]-PYRIMIDINE AND PYRAZOLO [1,5-a] [1, 3, 5]-TRIAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0105081A3 (en) Triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0203450A3 (en) Pyrazolo '4,3-d! pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them and their use
PT1382339E (pt) Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
HUP0301114A3 (en) Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them
HUP0200207A3 (en) Substituted 2-aryl-3-(hetroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compositions and methods for their preparation
HUP0001507A3 (en) Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
PL1622912T3 (pl) 2-ALKINYLO i 2-ALKENYLO-PIRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PIRYMIDYNY JAKO ANTAGONIŚCI RECEPTORA ADENOZYNOWEGO A2A
AU1224902A (en) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
IL172369A (en) History of 2-Transformed Phenyl-5, 7-Dialkyl-3, 7-Dihydropyrrolo- [3,2-d] Pyrimidin-4-Ven, process for their preparation, and pharmaceutical preparations containing them
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
WO2003053973A8 (de) Pyrazolyl-substituierte triazolochinoxaline
HK1085202A (en) Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished